

Freedom of Information Act 2000 – Request Reference FoI/24/233
Multiple Myeloma

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

161 patients.

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

- Belantamab Mafodotin [Blenrep] – 3
- Bortezomib [Velcade] monotherapy or with dexamethasone – 4
- Bortezomib, thalidomide and dexamethasone [VTD] – 0
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) – 5
- Carfilzomib [Kyprolis] and dexamethasone – 2
- Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone – 4
- Daratumumab [Darzalex] monotherapy – 13
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) – 21
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) – 5
- Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone – 11
- Elranatamab – 2
- Idecabtagene vicleucel [Abecma] – 0
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) – 3
- Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) – 16
- Lenalidomide [Revlimid] monotherapy – 18
- Lenalidomide [Revlimid] and dexamethasone – 18
- Pomalidomide [Imnovid] and dexamethasone – 11
- Selinexor and dexamethasone – 0
- Talquetamab – 2
- Teclistamab [Tecvayli] – 0
- Any other systemic anti-cancer therapy – 34